{"filings":[{"id":442518,"accession_number":"0001493152-26-023069","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2026-05-14T20:05:32+00:00","items":["5.03","9.01"],"status":"ready","headline":"Aspire Biopharma files 1-for-30 reverse stock split","event_type":"other_material","confidence":"high","bullets":["Filed 1-for-30 reverse stock split of common stock on May 11, 2026.","Fractional shares rounded up; no fractional shares will be issued in the split.","Ticker symbol remains ASBP; new CUSIP number is 738920305.","Effective date set in the Certificate of Amendment filed with Delaware Secretary of State."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96181,"accession_number":"0001493152-26-018018","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2026-04-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aspire Biopharma closes $21M private placement, secures $22.5M credit facility for DCS acquisition","event_type":"other_material","confidence":"high","bullets":["Closed second tranche of $10M (12,500 preferred shares); total gross proceeds $21M from private placement.","Commitment letter for up to $22.5M senior secured credit facility to fund proposed $30M cash acquisition of DCS.","DCS (automotive supplier) had $200M+ revenue and $20M+ adjusted EBITDA in FY2025 (unaudited).","Stockholders' equity now exceeds $2.5M Nasdaq minimum; no new equity anticipated to consummate DCS purchase."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96176,"accession_number":"0001493152-26-017145","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K/A","filed_at":"2026-04-17T23:59:59+00:00","items":["1.01","5.03","9.01"],"status":"ready","headline":"Aspire Biopharma closes second tranche of $21M preferred offering; funds Dura Driver acquisition","event_type":"other_material","confidence":"high","bullets":["Closed second tranche of Series A Convertible Preferred stock on April 15, 2026 for 12,500 shares and gross proceeds of ~$10M.","Combined with first tranche (13,750 shares, $11M), total offering raises $21M before fees.","Amended Certificate of Designation to increase authorized Series A shares from 25,000 to 30,000.","Net proceeds to fund cash portion of proposed Dura Driver Control Systems acquisition and for general corporate purposes.","RBW Capital Partners acting through Dawson James Securities acted as placement agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96180,"accession_number":"0001493152-26-017115","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["1.01","5.03","9.01"],"status":"ready","headline":"Aspire Biopharma closes $10M second tranche of Series A preferred offering; amends certificate","event_type":"other_material","confidence":"high","bullets":["Second closing issued 12,500 Series A Convertible Preferred Shares for gross proceeds of $10,000,000.","Combined with prior closing of 13,750 shares ($11M including $943,801 debt conversion), total 30,000 shares designated.","Company believes stockholders' equity now exceeds $2.5M minimum for continued Nasdaq listing.","Certificate of Amendment filed Apr 13, 2026 designating 30,000 Series A shares with $1,000 stated value each.","Conversion price set at 80% of lowest closing price over 5 days before conversion; floor price at 20% of Nasdaq Minimum Price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96179,"accession_number":"0001493152-26-017054","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Aspire Biopharma shareholders approve reverse stock split and authorized share increase","event_type":"other_material","confidence":"high","bullets":["Reverse stock split ratio range 1:5 to 1:500 approved: 2,096,356 for, 582,185 against, 12,852 abstain.","Authorized common stock increase from 490M to 700M shares passed: 1,925,368 for, 524,501 against, 7,403 abstain.","Series A Preferred issuance for conversion shares and floor price approved: 1,466,141 for, 203,756 against, 8,652 abstain, 1,012,844 broker non-votes.","ELOC Agreement share issuance approved: 1,469,985 for, 203,926 against, 4,638 abstain, 1,012,844 broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96178,"accession_number":"0001493152-26-016979","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aspire Biopharma signs LOI to acquire automotive supplier DCS for $30M; DCS had $200M+ revenue in FY2025","event_type":"m_and_a","confidence":"high","bullets":["Purchase price of $30M cash for 100% of DCS; DCS generated >$200M revenue and >$22M adjusted EBITDA in FY2025 (unaudited).","DCS is a tier-one auto supplier with 310 patents, 11 global facilities, serving 150+ vehicle platforms across major OEMs.","Management from Lakewood & Company (100+ years auto experience) to bolster DCS leadership; deal subject to due diligence and audit.","RBW Capital Partners is exclusive financial advisor; Dawson James Securities will provide brokerage services for the acquisition.","Aspire plans to become a diversified, high-revenue enterprise; no definitive agreement executed yet and no assurance of completion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96177,"accession_number":"0001493152-26-016683","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2026-04-15T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Aspire Biopharma signs LOI to acquire Driver Controls Systems unit for $30M","event_type":"m_and_a","confidence":"high","bullets":["Entered non-binding LOI to acquire Driver Controls Systems business unit of Firefish Topco for $30M cash-free, debt-free.","Purchase price payable in cash at closing; no new equity raise anticipated.","Break-up fees of $3.5M applicable under certain circumstances; 30-day no-shop period.","Company plans to engage Lakewood & Company for management services post-closing.","Acquisition subject to definitive agreement; LOI non-binding except for exclusivity, confidentiality, and break-up fees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109860,"accession_number":"0001493152-26-006343","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["1.01","3.02","8.01","5.02","7.01","9.01"],"status":"ready","headline":"Aspire Biopharma raises up to $21M via convertible preferred stock; board adds Balatsos","event_type":"other_material","confidence":"high","bullets":["Initial closing of 13,750 Series A Convertible Preferred Shares for $11M gross proceeds; up to $21M total available.","Preferred shares convertible into common at 80% of lowest 5-day VWAP prior to conversion, subject to 4.99% ownership cap.","Company expects to regain Nasdaq stockholders' equity compliance (min $2.5M) after the offering.","Donald G. Fell resigned from board; Philip Balatsos appointed to fill vacancy.","RBW Capital Partners acted as placement agent; proceeds to support operations and reduce legacy debt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109859,"accession_number":"0001493152-26-005640","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2026-02-06T23:59:59+00:00","items":["5.03","1.01","9.01"],"status":"ready","headline":"Aspire Biopharma files Series A Convertible Preferred Stock with 80% discount conversion and price protection","event_type":"other_material","confidence":"high","bullets":["Filed Certificate of Designation for 25,000 shares of Series A Convertible Preferred Stock on Feb 2, 2026.","Conversion price at 80% of lowest closing price in 5 prior trading days; floor price at 20% of Nasdaq minimum price.","Beneficial ownership conversion cap at 4.99% (can increase to 9.99% with 61-day notice).","Holders get participation rights in 30% of future financings for 6 months; no voting rights.","Shares rank senior to common; price protection adjusts conversion price on lower-priced issuances."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109858,"accession_number":"0001493152-26-004543","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Aspire Biopharma raises $2M via 8% OID debentures with 790K incentive shares","event_type":"debt","confidence":"high","bullets":["Issued $2,173,913 principal of 8% OID debentures for $2,000,000; maturity sooner of 90 days or $8M financing event.","Debentures are non-convertible, bear no interest; 790,000 shares of common stock issued as incentive shares.","Proceeds to be used for debt repayment and working capital; offering exempt under Section 4(a)(2)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109857,"accession_number":"0001493152-26-002326","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2026-01-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Aspire Biopharma Board sets share limit for 2024 Stock Incentive Plan at 4,890,000 shares","event_type":"other_material","confidence":"high","bullets":["Board confirmed share limit of 4,890,000 shares for the 2024 Stock Incentive Plan, which was approved by stockholders in Feb 2025.","Approved forms of Restricted Stock Unit and Stock Option award agreements under the Plan.","Plan allows grants of equity awards to employees, directors, and consultants to align with long-term stockholder interests."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109856,"accession_number":"0001493152-26-002057","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Aspire Biopharma director Surendra Ajjarapu resigns effective Jan 7, 2026","event_type":"leadership","confidence":"high","bullets":["Surendra Ajjarapu resigned as Director of Aspire Biopharma, effective January 7, 2026.","Resignation not due to any disagreement with the Company, Board, or management.","No replacement for the vacant director position has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109855,"accession_number":"0001493152-26-000518","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["1.01","3.02","2.03","9.01"],"status":"ready","headline":"Aspire Biopharma converts ~$1.75M debt from PowerUp sponsors into common stock","event_type":"other_material","confidence":"high","bullets":["Exchanged ~$1.75M debt for common stock at closing price less $0.01/share; holders can submit up to 4 exchange notices by Jan 31, 2026.","Each exchange notice limited to 30% of outstanding balance; shares are freely tradeable without restrictive legends.","Upon a financing over $3M, company may repay debt; holder can elect 25% of outstanding balance from proceeds.","Exchange exempt under Section 3(a)(9) of Securities Act; debt originated from 2024 subscription agreements with PowerUp sponsors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126397,"accession_number":"0001493152-25-022580","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["1.01","1.02","2.03","3.02","9.01"],"status":"ready","headline":"Aspire Biopharma enters $100M ELOC with Arena, terminates prior ELOC","event_type":"other_material","confidence":"high","bullets":["Entered into $100M equity line of credit (ELOC) with Arena Business Solutions, effective Nov 11, 2025.","Prior $100M ELOC with Arena dated Feb 13, 2025 mutually terminated on same day.","Company may sell shares at 96% of VWAP; maximum advance amount varies by time of notice (up to $20M).","Issued transaction fee shares and paid $40,000 in fees (cash and shares) to Arena.","ELOC term is 36 months; subject to ownership limitation of 9.99% and Nasdaq exchange cap until shareholder approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126396,"accession_number":"0001493152-25-020891","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Aspire Biopharma holders approve reverse split (1:5-1:40) and 19.99%+ note issuance","event_type":"other_material","confidence":"high","bullets":["Reverse stock split proposal passed: 24,965,481 for, 5,988,513 against, 29,704 abstain.","Notes proposal under Nasdaq Rule 5635(d) passed: 19,852,827 for, 3,747,867 against, 7,374,427 broker non-votes.","Reverse split ratio range 1:5 to 1:40; board has discretion to implement within one year.","Notes issued under Aug 19, 2025 purchase agreements; conversion floor price is 20% of 5-day avg closing prior to closing.","Ticker ASBP (common) and ASBPW (warrants) listed on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126395,"accession_number":"0001493152-25-018512","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2025-10-17T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nasdaq notifies Aspire Biopharma of delisting for MVLS and bid price non-compliance; company appeals","event_type":"regulatory","confidence":"high","bullets":["On Oct 15, 2025, Nasdaq Staff notified the Company of delisting due to failure to comply with the MVLS Rule ($50M minimum) and Bid Price Rule ($1.00 minimum).","The Company failed to regain compliance within the 180-day period that ended on October 13, 2025.","The Company requested a hearing before the Nasdaq Hearings Panel and paid a $20,000 fee, which stays the suspension pending the Panel's decision.","The Company will present a plan to regain compliance and may request an extension of up to 180 additional days.","There is no assurance that the Panel will grant continued listing or that compliance can be regained."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143154,"accession_number":"0001493152-25-015773","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["3.02","4.01"],"status":"ready","headline":"Aspire Biopharma dismisses auditor Bush, appoints Turner Stone; gets $1M funding tranche","event_type":"other_material","confidence":"high","bullets":["Dismissed Bush & Associates CPA as independent auditor effective Sept 22, 2025; 2024 audit included going concern explanatory paragraph.","Appointed Turner Stone & Co. as new independent auditor for FY 2025, effective Sept 22, 2025.","No disagreements with Bush; material weaknesses in internal control over financial reporting were disclosed.","Received $1M second tranche funding under Securities Purchase Agreement for notes with aggregate principal $9.6875M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143153,"accession_number":"0001641172-25-025257","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2025-08-22T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Aspire Biopharma raises $7.75M via convertible notes with 20% OID, maturity Feb 2026","event_type":"debt","confidence":"high","bullets":["Aggregate principal $9.6875M issued at $7.75M subscription price (20% OID) for three tranches.","Notes mature Feb 19, 2026; convertible at 80% of lowest closing price in prior 5 trading days.","Proceeds to pay off debt and for working capital; RBW Capital Partners received 8% commission.","Registration rights agreement requires resale registration statement filed by Sept 18, 2025.","Company may prepay at 20% premium; conversion capped at 4.99% (or 9.99%) beneficial ownership."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143152,"accession_number":"0001641172-25-021595","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CEO and two directors resign; interim CEO appointed; director cites irreconcilable differences","event_type":"leadership","confidence":"high","bullets":["Michael Howe steps down as CEO and Director effective July 24, 2025; no disagreement with company.","Kraig Higginson, Chairman, appointed Interim CEO; company searching for permanent CEO.","Gary Stein resigns as independent Director and Audit Committee chair; Howard Doss succeeds him.","Barbara Sher resigns as director citing irreconcilable differences with company policies and direction.","No disagreements cited for Howe or Stein; Sher's resignation letter provided to company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161272,"accession_number":"0001641172-25-015653","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aspire Biopharma moves principal executive office to Estero, Florida","event_type":"other","confidence":"high","bullets":["Board changed principal executive office to 23150 Fashion Drive, Suite 232, Estero, FL 33928 effective June 17, 2025.","Former address was 194 Candelaro Drive, #233, Humacao, Puerto Rico 00791.","New office is the company's principal place of business and headquarters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161271,"accession_number":"0001641172-25-014445","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2025-06-10T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Aspire Biopharma CEO Kraig Higginson Steps Down, Michael C. Howe Appointed as New CEO","event_type":"leadership","confidence":"high","bullets":["Kraig Higginson resigned as CEO effective June 10, 2025, and will serve as Executive Chairman.","Board appointed Michael C. Howe, previously an independent board member, as CEO effective June 10, 2025.","Howe led MinuteClinic from 19 clinics to sale to CVS in 2006, delivering nearly sixfold return for investors.","Howe has 40+ years experience at Procter & Gamble, PepsiCo, Arby's (CEO), and early-stage healthcare companies.","Press release issued June 10, 2025, detailing leadership transition and Howe's background."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}